Physicochemical characterization confirmed favorable properties, such as rapid disintegration, peptide stability, and good surface morphology
But until the research catches up, and regulation does, too, the risks belong entirely to the user and those risks are not completely theoretical
However, none are yet approved by the EMA or FDA specifically for the treatment of obesity, though trials in obese people without T2D have shown promising results [61]
Accessed January 12, 2025
Both medications require regular monitoring of blood glucose levels for effective diabetes management
We thank the core imaging facility of Institut Jacques Monod (ImagoSeine facility) for help in image acquisition and processing